Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Dec 15;100(12):3005–3013. doi: 10.1172/JCI119854

Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function.

V Large 1, L Hellström 1, S Reynisdottir 1, F Lönnqvist 1, P Eriksson 1, L Lannfelt 1, P Arner 1
PMCID: PMC508512  PMID: 9399946

Abstract

Catecholamines play a central role in the regulation of energy expenditure, in part by stimulating lipid mobilization through lipolysis in fat cells. The beta-2 adrenoceptor (BAR-2) is a major lipolytic receptor in human fat cells. To determine whether known polymorphisms in codons 16, 27, and 164 of this receptor play a role in obesity and subcutaneous adipocyte BAR-2 lipolytic function, we investigated a group of 140 women with a large variation in body fat mass. Only the polymorphisms in codons 16 and 27 were common in the study population. The Gln27Glu polymorphism was markedly associated with obesity with a relative risk for obesity of approximately 7 and an odds ratio of approximately 10. Homozygotes for Glu27 had an average fat mass excess of 20 kg and approximately 50% larger fat cells than controls. However, no significant association with changes in BAR-2 function was observed. The Arg16Gly polymorphism was associated with altered BAR-2 function with Gly16 carriers showing a fivefold increased agonist sensitivity and without any change in BAR-2 expression. However, it was not significantly linked with obesity. These findings suggest that genetic variability in the human BAR-2 gene could be of major importance for obesity, energy expenditure, and lipolytic BAR-2 function in adipose tissue, at least in women.

Full Text

The Full Text of this article is available as a PDF (254.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arner P., Hellmér J., Wennlund A., Ostman J., Engfeldt P. Adrenoceptor occupancy in isolated human fat cells and its relationship with lipolysis rate. Eur J Pharmacol. 1988 Jan 27;146(1):45–56. doi: 10.1016/0014-2999(88)90485-2. [DOI] [PubMed] [Google Scholar]
  2. Barbe P., Millet L., Galitzky J., Lafontan M., Berlan M. In situ assessment of the role of the beta 1-, beta 2- and beta 3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Br J Pharmacol. 1996 Mar;117(5):907–913. doi: 10.1111/j.1476-5381.1996.tb15279.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bouchard C. Long-term programming of body size. Nutr Rev. 1996 Feb;54(2 Pt 2):S8–16. doi: 10.1111/j.1753-4887.1996.tb03865.x. [DOI] [PubMed] [Google Scholar]
  4. Bouchard C., Pérusse L. Current status of the human obesity gene map. Obes Res. 1996 Jan;4(1):81–90. doi: 10.1002/j.1550-8528.1996.tb00516.x. [DOI] [PubMed] [Google Scholar]
  5. Candelore M. R., Deng L., Tota L. M., Kelly L. J., Cascieri M. A., Strader C. D. Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant. Endocrinology. 1996 Jun;137(6):2638–2641. doi: 10.1210/endo.137.6.8641219. [DOI] [PubMed] [Google Scholar]
  6. Clément K., Vaisse C., Manning B. S., Basdevant A., Guy-Grand B., Ruiz J., Silver K. D., Shuldiner A. R., Froguel P., Strosberg A. D. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med. 1995 Aug 10;333(6):352–354. doi: 10.1056/NEJM199508103330605. [DOI] [PubMed] [Google Scholar]
  7. Comuzzie A. G., Hixson J. E., Almasy L., Mitchell B. D., Mahaney M. C., Dyer T. D., Stern M. P., MacCluer J. W., Blangero J. A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2. Nat Genet. 1997 Mar;15(3):273–276. doi: 10.1038/ng0397-273. [DOI] [PubMed] [Google Scholar]
  8. Enocksson S., Shimizu M., Lönnqvist F., Nordenström J., Arner P. Demonstration of an in vivo functional beta 3-adrenoceptor in man. J Clin Invest. 1995 May;95(5):2239–2245. doi: 10.1172/JCI117914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fujisawa T., Ikegami H., Yamato E., Takekawa K., Nakagawa Y., Hamada Y., Oga T., Ueda H., Shintani M., Fukuda M. Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain. Diabetologia. 1996 Mar;39(3):349–352. doi: 10.1007/BF00418352. [DOI] [PubMed] [Google Scholar]
  10. Gagnon J., Mauriège P., Roy S., Sjöström D., Chagnon Y. C., Dionne F. T., Oppert J. M., Pérusse L., Sjöström L., Bouchard C. The Trp64Arg mutation of the beta3 adrenergic receptor gene has no effect on obesity phenotypes in the Québec Family Study and Swedish Obese Subjects cohorts. J Clin Invest. 1996 Nov 1;98(9):2086–2093. doi: 10.1172/JCI119014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gallagher D., Visser M., Sepúlveda D., Pierson R. N., Harris T., Heymsfield S. B. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol. 1996 Feb 1;143(3):228–239. doi: 10.1093/oxfordjournals.aje.a008733. [DOI] [PubMed] [Google Scholar]
  12. Green S. A., Cole G., Jacinto M., Innis M., Liggett S. B. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 1993 Nov 5;268(31):23116–23121. [PubMed] [Google Scholar]
  13. Green S. A., Turki J., Hall I. P., Liggett S. B. Implications of genetic variability of human beta 2-adrenergic receptor structure. Pulm Pharmacol. 1995 Feb;8(1):1–10. doi: 10.1006/pulp.1995.1001. [DOI] [PubMed] [Google Scholar]
  14. Green S. A., Turki J., Innis M., Liggett S. B. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994 Aug 16;33(32):9414–9419. doi: 10.1021/bi00198a006. [DOI] [PubMed] [Google Scholar]
  15. Hellmér J., Arner P., Lundin A. Automatic luminometric kinetic assay of glycerol for lipolysis studies. Anal Biochem. 1989 Feb 15;177(1):132–137. doi: 10.1016/0003-2697(89)90027-4. [DOI] [PubMed] [Google Scholar]
  16. Kenakin T. P. The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev. 1984 Sep;36(3):165–222. [PubMed] [Google Scholar]
  17. Kobilka B. K., Dixon R. A., Frielle T., Dohlman H. G., Bolanowski M. A., Sigal I. S., Yang-Feng T. L., Francke U., Caron M. G., Lefkowitz R. J. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A. 1987 Jan;84(1):46–50. doi: 10.1073/pnas.84.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lafontan M., Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res. 1993 Jul;34(7):1057–1091. [PubMed] [Google Scholar]
  19. Large V., Reynisdottir S., Eleborg L., van Harmelen V., Strömmer L., Arner P. Lipolysis in human fat cells obtained under local and general anesthesia. Int J Obes Relat Metab Disord. 1997 Jan;21(1):78–82. doi: 10.1038/sj.ijo.0800368. [DOI] [PubMed] [Google Scholar]
  20. Li L. S., Lönnqvist F., Luthman H., Arner P. Phenotypic characterization of the Trp64Arg polymorphism in the beta 3-adrenergic receptor gene in normal weight and obese subjects. Diabetologia. 1996 Jul;39(7):857–860. doi: 10.1007/s001250050521. [DOI] [PubMed] [Google Scholar]
  21. Liggett S. B. Genetics of beta 2-adrenergic receptor variants in asthma. Clin Exp Allergy. 1995 Nov;25 (Suppl 2):89–96. doi: 10.1111/j.1365-2222.1995.tb00431.x. [DOI] [PubMed] [Google Scholar]
  22. Reihsaus E., Innis M., MacIntyre N., Liggett S. B. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993 Mar;8(3):334–339. doi: 10.1165/ajrcmb/8.3.334. [DOI] [PubMed] [Google Scholar]
  23. Reynisdottir S., Ellerfeldt K., Wahrenberg H., Lithell H., Arner P. Multiple lipolysis defects in the insulin resistance (metabolic) syndrome. J Clin Invest. 1994 Jun;93(6):2590–2599. doi: 10.1172/JCI117271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sipiläinen R., Uusitupa M., Heikkinen S., Rissanen A., Laakso M. Polymorphism of the beta3-adrenergic receptor gene affects basal metabolic rate in obese Finns. Diabetes. 1997 Jan;46(1):77–80. doi: 10.2337/diabetes.46.1.77. [DOI] [PubMed] [Google Scholar]
  25. Spiegelman B. M., Flier J. S. Adipogenesis and obesity: rounding out the big picture. Cell. 1996 Nov 1;87(3):377–389. doi: 10.1016/s0092-8674(00)81359-8. [DOI] [PubMed] [Google Scholar]
  26. Turki J., Pak J., Green S. A., Martin R. J., Liggett S. B. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest. 1995 Apr;95(4):1635–1641. doi: 10.1172/JCI117838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Walston J., Silver K., Bogardus C., Knowler W. C., Celi F. S., Austin S., Manning B., Strosberg A. D., Stern M. P., Raben N. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med. 1995 Aug 10;333(6):343–347. doi: 10.1056/NEJM199508103330603. [DOI] [PubMed] [Google Scholar]
  28. Widén E., Lehto M., Kanninen T., Walston J., Shuldiner A. R., Groop L. C. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med. 1995 Aug 10;333(6):348–351. doi: 10.1056/NEJM199508103330604. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES